- Molecular NameAcamprosate
- Synonym3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; acamprosate; N-Acetylhomotaurine
- Weight181.212
- Drugbank_IDDB00659
- ACS_NO77337-76-9
- Show 2D model
- LogP (experiment)-0.96
- LogP (predicted, AB/LogP v2.0)-2.86
- pkaN/A
- LogD (pH=7, predicted)-6.94
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.74
- LogSw (predicted, AB/LogsW2.0)149.99
- Sw (mg/ml) (predicted, ACD/Labs)595.86
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds4
- TPSA91.85
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used for treating alcohol dependence.
- Absorption_value11.0
- Absorption (description)The absolute bioavailability of acamprosate after oral administration is about 11%. The food effect on absorption is not clinically significant and no adjustment of dose is necessary.
- Caco_2N/A
- Bioavailability11.0
- Protein binding0.0
- Volume of distribution (VD)72-109 liters (approximately 1 L/kg).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is not significantly metabolised
- Half life20~33 h
- ExcretionExcreted unchanged in urine.
- Urinary ExcretionN/A
- ClerancePlasma, 184 L/h (healthy volunteers); 16 L/h (patients with moderate renal impairment); 66.5 L/h (severe impairment).
- ToxicityIn all reported cases of acute overdosage with acamprosate (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with acamprosate was diarrhea.
- LD50 (rat)N/A
- LD50 (mouse)N/A